Lazard Asset Management
AZN icon

Lazard Asset Management’s AstraZeneca AZN Stock Holding History

Lazard Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$433M Buy
2,216,887
+1,548,279
+232% +$299M 0.71% 27
2025
Q4 		$123M Buy
668,608
+1,328
+0.2% +$233K 0.21% 111
2025
Q3 		$102M Buy
667,280
+103,825
+18% +$15.7M 0.14% 137
2025
Q2 		$78.7M Sell
563,455
-892
-0.2% -$125K 0.11% 160
2025
Q1 		$83M Buy
564,347
+105,014
+23% +$15.2M 0.13% 134
2024
Q4 		$60.2M Sell
459,333
-121,102
-21% -$17M 0.09% 172
2024
Q3 		$90.4M Sell
580,435
-379,883
-40% -$61.3M 0.12% 131
2024
Q2 		$150M Buy
960,318
+718,952
+298% +$108M 0.19% 104
2024
Q1 		$32.7M Buy
241,366
+64,308
+36% +$8.52M 0.04% 291
2023
Q4 		$23.8M Buy
177,058
+35,278
+25% +$4.59M 0.03% 351
2023
Q3 		$19.2M Buy
141,780
+62,257
+78% +$8.5M 0.03% 389
2023
Q2 		$11.4M Buy
79,523
+24,954
+46% +$3.67M 0.01% 532
2023
Q1 		$7.57M Buy
54,569
+52,638
+2,726% +$7.08M 0.01% 648
2022
Q4 		$260K Buy
1,931
+247
+15% +$31K ﹤0.01% 1250
2022
Q3 		$183K Hold
1,684
– – ﹤0.01% 1288
2022
Q2 		$221K Sell
1,684
-182
-10% -$23.9K ﹤0.01% 1256
2022
Q1 		$246K Sell
1,866
-26,967
-94% -$3.23M ﹤0.01% 1220
2021
Q4 		$3.36M Sell
28,833
-377,559
-93% -$44.4M ﹤0.01% 850
2021
Q3 		$48.8M Buy
406,392
+318,288
+361% +$37.1M 0.06% 287
2021
Q2 		$10.6M Buy
+88,104
New +$9.67M 0.01% 590
2016
Q3 		– Sell
-182
Closed -$10K – 986
2016
Q2 		$10K Buy
+182
New +$10.6K ﹤0.01% 954
2016
Q1 		– Sell
-15
Closed -$1K – 1037
2015
Q4 		$1K Buy
+15
New +$983 ﹤0.01% 1069
2013
Q3 		– Sell
-59
Closed -$2K – 956
2013
Q2 		$2K Buy
+59
New +$3K ﹤0.01% 1007

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Lazard Asset Management's AZN Position: Q1 2026 in Review

Lazard Asset Management increased its AstraZeneca (AZN) stake by 232% in Q1 2026, buying an estimated $299M and bringing the position to 2,216,887 shares worth $433M. The position accounts for 0.71% of the portfolio, ranked #27.

Lazard Asset Management first reported a position in AZN in Q2 2013 and has held it in 23 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Lazard Asset Management held 2,216,887 shares of AstraZeneca worth $433M as of Q1 2026.
  • Lazard Asset Management bought 1,548,279 AstraZeneca shares in Q1 2026, an estimated $299M.
  • AstraZeneca made up 0.71% of Lazard Asset Management's portfolio in Q1 2026, its #27 holding.
  • Lazard Asset Management first reported a position in AstraZeneca in Q2 2013 and has held it in 23 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.